Paul O'Brien to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Paul O'Brien has written about Xenograft Model Antitumor Assays.
Connection Strength
0.037
-
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res. 2019 02 15; 25(4):1156-1164.
Score: 0.037
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.